These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
149 related items for PubMed ID: 6956430
1. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Bolin RW, Robinson WA, Sutherland J, Hamman RF. Cancer; 1982 Nov 01; 50(9):1683-6. PubMed ID: 6956430 [Abstract] [Full Text] [Related]
2. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Rushing D, Goldman A, Gibbs G, Howe R, Kennedy BJ. Am J Clin Oncol; 1982 Jun 01; 5(3):307-13. PubMed ID: 6952759 [Abstract] [Full Text] [Related]
3. Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders. Baron BW, Mick R, Baron JM. Cancer; 1993 Aug 15; 72(4):1209-18. PubMed ID: 8339212 [Abstract] [Full Text] [Related]
4. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L, Kolb HJ, Meyer P, Essers U, Queisser U, Vaupel H. Blut; 1988 Feb 15; 56(2):87-91. PubMed ID: 3277680 [Abstract] [Full Text] [Related]
5. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Heinze B, Georgii A. Blood; 1993 Jul 15; 82(2):398-407. PubMed ID: 8329700 [Abstract] [Full Text] [Related]
6. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Hehlmann R, Heimpel H, Kolb HJ, Heinze B, Hochhaus A, Griesshammer M, Pralle H, Queisser WP, Essers U, Falge C. Leuk Lymphoma; 1993 Jul 15; 11 Suppl 1():159-68. PubMed ID: 8251890 [Abstract] [Full Text] [Related]
7. [Prognostic factors in chronic myeloid leukemia. Apropos of 798 cases]. Jacquillat C, Chastang C, Bancalari G, Weil M, Bernard J. Ann Med Interne (Paris); 1975 Jul 15; 126(6-7):515-20. PubMed ID: 1065252 [No Abstract] [Full Text] [Related]
8. [Prospective controlled study of therapy of chronic myeloid leukemia (CML)]. Hehlmann R, Heimpel H, Hossfeld DK, Köpcke W, Kolb HJ, Löffler H, Pralle H, Queisser W, Anger B, Bergmann L. Onkologie; 1987 Feb 15; 10(1):28-33. PubMed ID: 3295623 [Abstract] [Full Text] [Related]
10. [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897]. Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L, Kolb HJ, Meyer P, Essers U, Queisser U, Vaupel H. Onkologie; 1988 Feb 15; 11(1):25-9. PubMed ID: 3283622 [Abstract] [Full Text] [Related]
12. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. Olsson-Strömberg U, Simonsson B, Ahlgren T, Björkholm M, Carlsson K, Gahrton G, Hast R, Löfvenberg E, Linder O, Ljungman P, Malm C, Paul C, Rödjer S, Turesson I, Udén AM, Wahlin A, Killander A, Wadman B, Westin J, Vikrot O, Zettervall O, Oberg G, Swedish CML Study Group. Hematol J; 2004 Jul 15; 5(6):462-6. PubMed ID: 15570285 [Abstract] [Full Text] [Related]
13. Hydroxyurea, leucopheresis, and splenectomy in chronic myeloid leukaemia at the problastic phase. Schwarzenberg L, Mathé G, Pouillart P, Weiner R, Locour J, Genin J, Schneider M, De Vassal F, Hayat M, Amiel JL, Schlumberger JR, Jasmin C, Rosenfeld C. Br Med J; 1973 Mar 24; 1(5855):700-3. PubMed ID: 4512003 [Abstract] [Full Text] [Related]
14. [The analysis of failures in the treatment of children with chronic myelocytic leukemia in the studies of Polish pediatric leukemia/ lymphoma group]. Chybicka A, Bogusławska-Jaworska J, Kałwak K, Turkiewicz D, Armata J, Balcerska A, Cwiklińska M, Hicke-Roberts A, Kaczmarek-Kanold M, Kołecki P, Kowalczyk J, Krauze A, Matysiak M, Płoszyńska A, Rokicka-Milewska R, Sońta-Jakimczyk D, Sikorska-Fic B, Wiśniewska-Slusarz H, Wysocki M, Wachowiak J. Wiad Lek; 1998 Mar 24; 51 Suppl 4():33-9. PubMed ID: 10731941 [Abstract] [Full Text] [Related]
15. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ. Acta Haematol; 1987 Mar 24; 78 Suppl 1():70-4. PubMed ID: 2449026 [Abstract] [Full Text] [Related]
16. [Survival in chronic myeloid leukemia following aplasia caused by Misulban]. Perreau P, Gardais J. Sem Hop; 1969 Mar 26; 45(15):964-70. PubMed ID: 4307171 [No Abstract] [Full Text] [Related]
17. Splenic irradiation following chemotherapy in chronic myelogenous leukemia. Wilson JF, Johnson RE. Radiology; 1971 Dec 26; 101(3):657-61. PubMed ID: 5288778 [No Abstract] [Full Text] [Related]
18. Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase. Baker MA, Taub RN, Carter WH, Davidson M, Sutton DM, Kutas G, Berger S, Watt HJ. Cancer Res; 1984 Jan 26; 44(1):383-5. PubMed ID: 6360347 [Abstract] [Full Text] [Related]
19. A retrospective study of patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Medical Center during the years 1966-76. Inbal A, Modan M, Many A. Isr J Med Sci; 1978 Dec 26; 14(12):1259-64. PubMed ID: 285048 [Abstract] [Full Text] [Related]
20. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Bundschuh S, Biermann T, Roessler G, Wasmus M, Diehl V, Zankovich R, Schaefer HE. Am J Clin Pathol; 2000 Jul 26; 114(1):57-65. PubMed ID: 10884800 [Abstract] [Full Text] [Related] Page: [Next] [New Search]